Pfizer has halted the development of its daily anti-obesity pill, danuglipron, due to a potential drug-induced liver injury in a clinical trial participant. The company plans to continue exploring other obesity treatments but has faced challenges in the market, where injectable treatments dominate. Despite the promise of oral medications, many patients struggle with access and affordability. Teljes cikk (Euronews.com)